Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Tarquinio

Neurology with Special Qualifications in Child Neurology Gainesville, GA Doctor of Osteopathy

NPI 1427131168 CMS profile 403584

1315 Jesse Jewell Pkwy Ne Ste 300, Gainesville, GA 30501

Open in the dashboard

General payments

$50,130

271 records reported · program years 2019–2025

Research payments

$72,296

Paid to them · 10 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$587,430 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Daniel Tarquinio of Gainesville, GA is reported in the CMS Open Payments database as having received $50,130 across 271 general payments and $72,296 in research payments paid to them. Separately, studies naming them as principal investigator received $587,430 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,241 100
2024 General $10,235 78
2023 General $9,245 55
2022 General $8,905 12
2022 Research $67,921 8
2021 General $4,718 11
2021 Research $700 1
2020 General $6,333 11
2019 General $3,453 4
2019 Research $3,675 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Tarquinio
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Daniel Tarquinio were reported at $7,241. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Daniel Tarquinio Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $3,453 $262 $68–$1,313 $163
2020 $6,333 $188 $46–$1,222 $114
2021 $4,718 $183 $45–$1,356 $132
2022 $8,905 $229 $72–$1,177 $149
2023 $9,245 $269 $93–$1,195 $160
2024 $10,235 $300 $98–$1,428 $164
2025 $7,241 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurelis, Inc. $33,838 64 payments
  2. AbbVie, Inc. $7,751 72 payments
  3. ACADIA Pharmaceuticals Inc $2,954 18 payments
  4. Cipla USA Inc. $2,567 1 payment
  5. Pfizer Inc. $524 36 payments
  6. Marinus Pharmaceuticals, Inc. $513 2 payments
  7. UCB, Inc. $367 14 payments
  8. SK Life Science, Inc. $257 9 payments
  9. Jazz Pharmaceuticals Inc. $241 5 payments
  10. Argenx US, Inc. $174 7 payments
  11. Other $944 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $32,009 23 payments
  2. Consulting Fee $12,580 8 payments
  3. Food and Beverage $4,939 237 payments
  4. Travel and Lodging $602 3 payments
Products named General payments · program years 2019–2025
  1. VALTOCO $33,838 64 payments
  2. QULIPTA $558 52 payments
  3. NURTEC ODT $524 36 payments
  4. ZAVZPRET $371 24 payments
  5. UBRELVY $335 36 payments
  6. DAYBUE $308 14 payments
  7. BOTOX $267 13 payments
  8. Epidiolex $241 5 payments
  9. Briviact $159 6 payments
  10. Fintepla $143 6 payments
  11. Other $1,283 63 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Neurelis, Inc. $67,921 8 payments
  2. Biogen, Inc. $4,375 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 68 drugs

Part D claims

3,537

Median for Neurology: 833

Drug cost

$1,092,589

Median for Neurology: $202,670

Branded share of claims

28.5%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 26 $370,817
Ingrezza Valbenazine Tosylate Brand 16 $204,076
Tecfidera Dimethyl Fumarate Brand 11 $96,598
Aimovig Autoinjector Erenumab-Aooe Brand 70 $58,003
Xcopri Cenobamate Brand 41 $41,226
Epidiolex Cannabidiol (Cbd) Brand 13 $38,642
Botox Onabotulinumtoxina Brand 13 $32,534
Ubrelvy Ubrogepant Brand 21 $29,660
Ajovy Autoinjector Fremanezumab-Vfrm Brand 28 $25,913
Nurtec Odt Rimegepant Sulfate Brand 16 $22,691

The 10 drugs with the highest cost, of 68 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 16 billing codes

Paid by Medicare

$67,892

Medicare's payments for the services billed

Medicare patients

242

Average age 73

Services billed

3,145

138 women, 104 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 48%
Chronic kidney disease 35%
Depression 34%
Diabetes 31%
Ischemic heart disease 31%
Alzheimer's or dementia 26%
Osteoporosis 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VALTOCO
  • Neurelis, Inc. $6,339
$6,339 23 —
QULIPTA
  • AbbVie, Inc. $137
$137 — —
NURTEC ODT
  • PFIZER INC. $108
$108 16 —
UBRELVY
  • AbbVie, Inc. $91
$91 21 —
ZAVZPRET
  • PFIZER INC. $90
$90 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

281 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record